Anzeige
Mehr »
Donnerstag, 09.07.2026 - Börsentäglich über 12.000 News
Paukenschlag! Diese Gratis-Aktien könnten jetzt Gold wert sein
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
402 Leser
Artikel bewerten:
(1)

Cansativa GmbH: Significant next step to professionalize medical cannabis market: Cansativa and DaVinci announce partnership for development & production of medical cannabis vaporizers

FRANKFURT AM MAIN, Germany, Sept. 24, 2019 (GLOBE NEWSWIRE) -- Cansativa GmbH expands its portfolio with its Cansativa Medical Devices business. Medical devices entrepreneur Dr. Markus Haller becomes managing director. In cooperation with DaVinci, Cansativa Medical Devices launches its own cannabis vaporizer developed exclusively for medical purposes.

Cansativa's mission is to professionalize the medical cannabis industry and to play a pioneering role in this market. A team of health technology specialists at Cansativa Medical Devices is currently developing based on DaVinci's state-of-the-art evaporator technology and its own intellectual property new certified medical devices. Benedikt Sons, Co-Founder of Cansativa, underlines:

"This partnership brings us a big step closer to the realization of our vision of safe access to medical cannabis for a larger group of patients. With the development of a state-of-the-art medical vaporizer, the young industry will become even more professional."

Evaporation is particularly fit for medical purposes, as no toxic combustion substances are produced. The active ingredients tetrahydrocannabinol (THC) and cannabidiol (CBD) can thus be efficiently and safely administered. As health insurance companies cover the costs of the medical vaporizers, a fast and easy distribution among patients is possible.

Unlike other medical cannabis wholesalers, Cansativa takes a new approach: Through vertical integration, the company takes on key responsibilities along the entire value chain. With its new product lines, the company consistently expands its business model and demonstrates once again its operational excellence. Cansativa's founders are delighted to announce Dr. Markus Haller taking over the management of Cansativa Medical Devices. Dr. Markus Haller emphasizes:

"Thanks to this partnership, we have secured access to vaporizers as medical devices for patients worldwide. As an owner-managed company, we aim to have a long-term impact. We bolster our commitment to making the Cansativa Group a sustainable and strong enterprise."

Companies

Cansativa GmbH
Cansativa provides independent market access and extensive warehousing and distribution capacities. Founded in 2017, Cansativa is a GDP-certified pharmaceutical wholesaler licensed for trade in controlled substances and headquartered in Frankfurt am Main, Germany. Cansativa is committed to the goal of professionalizing the medical cannabis market, eliminating stigmatization surrounding it, and reducing prices for patients. Since the very beginning, Cansativa has operated its own distribution and fulfillment center, and as one of the "first movers" in the industry, it has become one of the largest importers and distributors of medical cannabis in Germany. From its location in Frankfurt am Main, the company supplies pharmacies and pharmaceutical wholesalers throughout Germany. With the ongoing expansion of a second GMP/GDP site in the Rhine-Main area Cansativa creates even more import, distribution and warehousing capacities. Cansativa's founding team and newest addition, Cansativa Medical Devices, continues to expand, based on two generations of expertise in the fields of medicine, law, and strategy, as well as engineering and medical devices technology

DaVinci Vaporizer
DaVinci Vaporizer is an American manufacturer of advanced vaporizer products and accessories based in Las Vegas, Nevada. The company was founded in 2011 by today's CEO Cortney Smith. DaVinci has set itself the mission to develop a vaporization experience that delivers unprecedented levels of purity and precision. With a focus on superior craftmanship, the use of finest components or the development of unique software, a unique experience should be created.

Press contact:
Thorsten Plath, Partner J+K
Cansativa@jk-kom.de
+49 (0) 163 883 8001

© 2019 GlobeNewswire (Europe)
SpaceX-Hype zu teuer – Diese 5 Aktien bieten bessere Chancen
Raumfahrt-Aktien gehören aktuell zu den heißesten Wetten an den Börsen. Spätestens mit dem spektakulären Börsengang von SpaceX ist der Sektor endgültig im Fokus der Anleger angekommen. Fantasien rund um Satellitenkommunikation, Rechenzentren im All und neue Geschäftsmodelle treiben die Kurse immer weiter nach oben.

Doch während die Begeisterung steigt, werden auch die Risiken größer. Viele Space-Start-ups sind inzwischen extrem hoch bewertet, arbeiten noch nicht profitabel und hängen stark von stetigem Kapitalzufluss ab. Schon kleine Rückschläge könnten die ambitionierten Wachstumspläne ins Wanken bringen.

Für Anleger, die vom Boom der Raumfahrt profitieren wollen, lohnt sich daher ein Perspektivwechsel. Statt auf überhitzte Pure Plays zu setzen, rücken etablierte Konzerne in den Fokus – Unternehmen mit jahrzehntelanger Erfahrung, stabilen Cashflows und engen Verbindungen zu Raumfahrtagenturen wie NASA und ESA.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau dieses Profil erfüllen: solide bewertet, operativ stark und bestens positioniert, um langfristig vom Space-Boom zu profitieren.

Jetzt den kostenlosen Report sichern – bevor der Markt die versteckten Gewinner entdeckt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.